Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H16N2O3 |
| Molecular Weight | 224.2563 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)C1=CC=C(C=C1)[N+]([O-])=O
InChI
InChIKey=UAORFCGRZIGNCI-UHFFFAOYSA-N
InChI=1S/C11H16N2O3/c1-8(2)12-7-11(14)9-3-5-10(6-4-9)13(15)16/h3-6,8,11-12,14H,7H2,1-2H3
Nifenalol is the beta-receptor antagonist. It has optical isomers. The racemic mixture and the levo-isomer are active in antagonizing beta-receptors, but the dextro-isomer is inactive. The levo-isomer seems to be about twice as active in blocking beta-receptors as the racemate. Nifenalol is virtually devoid of local anesthetic properties in contrast to procaine, propranolol, and butidrine. Nifenalol exacerbated the fighting behavior in male mice by foot-shock. Nifenalol has been studied in patients with coronary artery disease. It afforded the coronary patient good protection against angina and ischemic changes in the EKG. It was further noted that nifenalol had no antiarrhythmic action and that it was devoid of evident side effects. Nifenalol possessed weak action against tremorine and oxotremorine induced tremor.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Arrhythmogenic effect of beta-adrenoceptor-blocking drugs in Purkinje fibres of guinea-pig hearts. | 1996-01-01 |
|
| Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. | 1988-12 |
|
| Effects of bucumolol, nadolol and nifenalol on maximum upstroke velocity of action potential in guinea pig papillary muscles. | 1986-03 |
|
| [Iatrogenic dermatoses caused by beta-blocking drugs]. | 1983-11-01 |
|
| Effects of 1-(4-nitrophenyl)-2-isopropylaminoethanol (INPEA) and propranolol and their dextro-isomers on hemodynamic and metabolic responses to isoproterenol in dogs. | 1983-08 |
|
| Potentiating effect of (+) INPEA on prostaglandin analogue evoked contractions of isolated rat uterus. | 1983-03 |
|
| Sensitization by (+) Inpea of rat stomach strip contraction induced by PGE2 or pleural exudates. | 1981-07 |
|
| [Action of propranolol, nifenalol, and pindolol on the lipolytic effect of adrenaline in the rat epididymis]. | 1981-04 |
|
| Effect of (+) INPEA, (+) sotalol and deoxysotalol on the in vitro production of prostaglandins E and F by the rat uterus. | 1980-04 |
|
| Differentiation of beta-adrenoceptors in right atrium, diaphragm and adipose tissue of the rat, using stereoisomers of propranolol, alprenolol, nifenalol and practolol. | 1977-07-01 |
|
| [Blood glucose concentration and insulin activity in serum after administration of the beta receptor blockader nifenalol-HC1 (INPEA). Studies in metabolically healthy people and diabetics]. | 1977-06 |
|
| [Influence of the beta-receptor blocker nifenalol on insulin secretion in normal subjects and diabetic patients (author's transl)]. | 1977-02 |
|
| Cardiac action of carazolol and methypranol in comparison with other beta-receptor blockers. | 1977 |
|
| Tremorine-oxotremorine-induced tremor, hypothermia and analgesia, and physostigmine toxicity, in mice after pretreatment with beta-adrenoceptor antagonists. | 1976-04 |
|
| Blockade of epinephrine- and ouabain-induced cardiac arrhythmias in the dog heart-lung preparation. | 1966-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6688273
Dog: 5 or 15 mg/kg
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2872598
The effects of nifenalol (NIF) on contractile forces and on action potentials (APs) were investigated in isolated guinea pig atrial and papillary muscles, respectively. Log 1/ED40 values for the negative inotropic effects of this drug was 0.74 mmol/l in this order. NIF (0.2 mmol/l) produced about 20% reduction of Vmax at 1 Hz.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D1DE63830P
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
m1218
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB09255MIG
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
7413-36-7
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
100000084402
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
6317
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
C100250
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
C76554
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
3380
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
231-023-6
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
DTXSID9048693
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
Nifenalol
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL127349
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY | |||
|
2734
Created by
admin on Mon Mar 31 18:05:56 GMT 2025 , Edited by admin on Mon Mar 31 18:05:56 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)